Journals / Türk Nöroloji Dergisi / 2016 / Cilt: 22 - Sayı: 4

Dirençli Migrenin Profilaktik Tedavisinde Abobotulinum Toksin A Etkisi

The Effect of Abobotulinum Toxin A in the Prophylactic Treatment of Refractory Migraine

Pages
156–160
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The average number of attacks per month before injection was 7.56±4.06, which decreased to 1.89±1.32 3 months after injection (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Some patients with migraine headache still experience severe migraine attacks despite use of proper prophylactic treatments.
📊
Key Findings & Data:Materials and Methods: In this prospective single-arm clinical trial, 18 patients with RM were included.
💡
Conclusion & Impact:Results: The average number of attacks per month before injection was 7.56±4.06, which decreased to 1.89±1.32 3 months after injection (p
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Some patients with migraine headache still experience severe migraine attacks despite use of proper prophylactic treatments. There are several treatments for refractory migraine (RM), one of which is abobotulinum toxin A (Dysport). This study aimed to investigate the efficacy of abobotulinum toxin A in the prophylactic treatment of RM. Materials and Methods: In this prospective single-arm clinical trial, 18 patients with RM were included. Patients completed a questionnaire including migraine characteristics one month before the study. Each patient received an injection of 150 U abobotulinum toxin A in the specific head and neck regions. Before and 3 months after treatment, migraine severity was evaluated. Results: The average number of attacks per month before injection was 7.56±4.06, which decreased to 1.89±1.32 3 months after injection (p

Özet

Amaç: Migren hastalarının bir kısmı uygun profilaktik tedavi kullanımına rağmen ciddi migren atakları yaşamaya devam etmektedirler. Dirençli migrende kullanılan çeşitli tedaviler vardır ve bunlardan birisi abobotulinum toksin A'dır (Dysport). Bu çalışmada dirençli migrenin profilaktik tedavisinde abobotulinum toksin A'nın etkinliğinin araştırılması hedeflenmiştir. Gereç ve Yöntem: Bu prospektif tek kollu klinik çalışmaya 18 dirençli migren hastası dahil edildi. Hastalar çalışmadan 1 ay önce migren karakteristiklerini içeren bir anketi tamamladılar. Her hastanın spesifik baş ve boyun bölgelerine 150 U abobotulinum toksin A enjeksiyonu uygulandı. Tedavi öncesi ve 3 ay sonrasında migren şiddeti değerlendirildi. Bulgular: Enjeksiyon öncesi aylık ortalama atak sayısı 7,56±4,06 iken, enjeksiyondan 3 ay sonra bu sayı 1,89±1,32'ye geriledi (p

🔖

Cite This Article

HOMAM, S. M., KHORASHADİZADEH, M., BAF, M. M. F., SAADAT, M. B., ALİPOUR, A. (2022). Dirençli Migrenin Profilaktik Tedavisinde Abobotulinum Toksin A Etkisi. Türk Nöroloji Dergisi, Cilt: 22 - Sayı: 4, 156–160. https://ajindex.com/articles/636916

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-315.
  2. Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother 2009;9:369-379.
  3. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-276. Ford ES, Li C, Pearson WS, Zhao G, Strine TW, Mokdad AH. Body mass index and headaches: findings from a national sample of US adults. Cephalalgia 2008;28:1270-1276.
  4. Lipton RB, Bigal ME. Toward an epidemiology of refractory migraine: current knowledge and issues for future research. Headache 2008;48:791- 798. Robbins L. Refractory Chronic Migraine. Practical Pain Management 2010;10:1-20. Available from: http://www.practicalpainmanagement.com/ pain/headache/migraine/refractory-chronic-migraine Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-450. Rapoport AM. New acute treatments for headache. Neurol Sci 2010;31(Suppl 1):S129-132. Headache Classification Subcommittee of the International Headache S. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160.
  5. Schulman EA, Lake AE, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, Lipton RB. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache 2008;48:778-782.
  6. Ravenni R, De Grandis D, Mazza A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci 2013;34:1043-1048.
  7. Sikaroudi H, Fathi D, Lotfi J. The effect of botulinum toxin type A injection as a prophylaxis drug for migraine headache. Tehran University Medical Journal 2004;62:432-441.
  8. Robertson CE, Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat 2012;8:35- 48. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42.
  9. Cui M, Li Z, You S, Khanijou S, Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of